ERBB2 and breast carcinoma: Based on the status of hormone receptors (ER and PR) and HER2, four principal molecular subtypes [luminal-A, -B, HER2-enriched and triple-negative breast cancer (TNBC)] have been characterized and are routinely used to predict prognosis and optimize adjuvant therapy in breast cancer [37].